

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3849299
<b>Application Number:</b>	10679699
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2007
<b>Title of Invention:</b>	Diagnosis and monitoring of diseases
<b>First Named Inventor/Applicant Name:</b>	David Bar-Or
<b>Customer Number:</b>	22442
<b>Filer:</b>	David Lawrence Walker/Debra Kesner
<b>Filer Authorized By:</b>	David Lawrence Walker
<b>Attorney Docket Number:</b>	4172-85
<b>Receipt Date:</b>	27-AUG-2008
<b>Filing Date:</b>	02-OCT-2003
<b>Time Stamp:</b>	16:12:15
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	McCain_Int_J_Immunopharmac.pdf	312167 6d26489748b6d8ba25c4b2956d153c3d813d36d8f	no	4

**Warnings:**

**Information:**

2	NPL Documents	McCain_Life_Science.pdf	624857 050b2f8a6c8b10240813e8a764939b6912067605	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	MeSH_Autoimmune_Diseases.pdf	52520 a98a9868c8cb659113b8ec5d585482109c1a4d	no	2
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Miller_Peptide_Inhibitor.pdf	451937 6e743244657f1c73746a6d5f3c4928ec0f8c24aa	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	MILNE_J_Pharm.pdf	923183 b5bca17518e9825d9176dd381b2810dccc8fb2f55	no	7
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Nitecki_J_Org_Chem.pdf	356289 95117b647d66236256c44bf89c380c6d1f7f88c	no	3
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Palacios_Tenidap.pdf	1204710 649ec35a88819ec9227962bba45b34b7535432f	no	10
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	PRASAD_Increased_cerebrospinal.pdf	444876 177b6452d330918113ba267ad7d881cc6645358	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	PURVES_Life_the_Science.pdf	177041 cab7b97c48b707c66ed7d86abc688f9151048c	no	3
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Rainger_Endothelial-Borne.pdf	1000214 812ac86a30a93c468f6c111c741e1f19f548ad	no	10
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	Rainsford_Effects_of_5-Lipoxygenase.pdf	608578 486368ace49da712b152a2e21bcafa0559ef	no	10
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Roth_Platelet-Activating.pdf	977451 68884c62aa19c3d7d788646c8d4cdad4921529ac	no	13
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	SAKURADA_J_Pharm.pdf	240855 7825c446fb515b64114d1188671baf775d1259a8	no	2
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Sakuta_Dual_Regulator.pdf	794256 916d8efed86aafbb8fc713c76a2eccee7e73870	no	10
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Sano_Process_Research.pdf	542564 0e0d32d412e7b3841a5a6c5f8e958cd2ef409c	no	6
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Shimazaki_Diketopiperazine_Derivatives.pdf	189515 47cd2d7af84f5020c4f55b3d825eeeb08b1163	no	4
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Shimazaki_Diketopiperazines.pdf	546734 86545c1aad4c1d6f6db0703b880a5232c374460	no	4
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Shimazaki_PAF.pdf	307684 023c5ac1265771ba6634bf096649a53978adeac631	no	4
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Smith_Lesson_10.pdf	620505 e8f94c2abede998020130e481103d81a3c0116a81c	no	9
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	Smith_Bioorg_Med_Chem.pdf	250328 8e0394068c3240e7304205f01c0a02420c4601	no	6
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Smith_Darlington.pdf	1119346 86edbf59e0c0c38c3825c2c63a12009f157	no	12
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	t_Hart_DDT.pdf	765130 0f0b5cf0ac2077770c73b4a2358013d131667a130	no	8
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	The_Cytokine_Handbook_Volume_I_167-199_456-474_567-601.pdf	17710002 930ebad8e170573dc91e44c5dc8de908b855d33	no	80
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	The_Cytokine_Handbook_Volume_II_838-860_and_1189-1211.pdf	11021740 13c71deb0f389a2b5be1051dc00a6931796608b	no	49
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	UNAL_Brain.pdf	661909 65516c3bc9dbb6b681e0f0838ccdf58fde0c51d	no	8
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	WALTER_PNAS.pdf	702919 53b153e098d774720d74528101b051adccc0b29	no	5
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Yoshida_PAF.pdf	446634 b29734c083c4d5317301095706a113f33f5bdc9	no	9
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	4172-85-PCT_Search_Report.pdf	582591 e0d0757361a39934323663093dc01994202a113	no	6
<b>Warnings:</b>					
<b>Information:</b>					

29	NPL Documents	4172-85-PCT_IPER.pdf	577067 a036a6179a08c69c72ba3ce39fb362dfb76a8ba	no	7
Warnings:					
Information:					
30	NPL Documents	4172-85-PAU_OA_6-16-08.pdf	182602 2221e0c08fb17596c42aa300c1e0cd302a036	no	2
Warnings:					
Information:					
31	NPL Documents	4172-85-PEP_SR_5-6-08.pdf	229914 4e598533fe0edf8341d1d11318e0cda8f7a0d	no	8
Warnings:					
Information:					
32	NPL Documents	4172-85-PNZ_OA_5-10-06.pdf	184153 26c294bc7a9b8c59abdc5130c6905da024221c0bf	no	2
Warnings:					
Information:					
33	NPL Documents	4172-85-PNZ_OA_01-10-08.pdf	132856 cd00c4eb307512bea5aa2ce048eb3e7b5f9c0ab	no	2
Warnings:					
Information:					
34	NPL Documents	4172-85-PNZ_OA_05-20-08.pdf	799395 ea11ac2bab16562b74c13a07652ec94ccfc3da	no	9
Warnings:					
Information:					
Total Files Size (in bytes):			45742522		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.